Results 221 to 230 of about 16,422,172 (350)

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

open access: yesMolecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir   +12 more
wiley   +1 more source

Publisher Correction: The bandgap-detuned excitation regime in photonic-crystal resonators

open access: yesNature Communications
Yan Jin   +6 more
doaj   +1 more source

Observation of Kerr soliton microcomb locked with a phonon laser. [PDF]

open access: yesSci Adv
Li X   +7 more
europepmc   +1 more source

On Adjusting the Hodrick-Prescott Filter for the Frequency of Observations

open access: yesReview of Economics and Statistics, 2002
Morten O. Ravn, H. Uhlig
semanticscholar   +1 more source

Repeated Games with Frequent Signals [PDF]

open access: yes
David K Levine, Drew Fudenberg
core  

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

open access: yesMolecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson   +2 more
wiley   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy